Search Results - t+cells

6 Results Sort By:
Methods of Producing Thymic Emigrants from Induced Pluripotent Stem Cells
Abstract: Hematopoietic and pluripotent stem cells can be differentiated into T cells with potential clinical utility. Current approaches for in vitro T cell production rely on Notch signaling and artificial mimicry of thymic selection. However, these approaches result in unconventional or phenotypically aberrant T cells; which may lead to unpredictable...
Published: 4/22/2025   |   Inventor(s): Raul Sakoda, Nicholas Klemen, Nicholas Restifo
Keywords(s): DIFFERENTIATION, Induced Pluripotent Stem Cells, IPSCS, RESEARCH MATERIAL, Restifo, T Cells, Thymic Environment, Tool
Category(s): TherapeuticArea > Infectious Disease, Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Licensing
A Dendritic Cell Vaccine to Immunize Cancer Patients Against Mutated Neoantigens Expressed by the Autologous Cancer
Abstract: Vaccines against non-viral cancers target mainly differentiation antigens, cancer testis antigens, and overexpressed antigens.  One common feature to these antigens is their presence in central immunological tolerance. Using these vaccines, T cells underwent depletion of high avidity clones directed against such antigens. This depletion can...
Published: 4/22/2025   |   Inventor(s): Gal Cafri, Paul Robbins, Jared Gartner, Steven Rosenberg
Keywords(s): CANCER, Dendritic cells, Immunotherapy, Neoantigens, Rosenberg, T Cells, vaccines
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Vaccines
In vitro Generation of an Autologous Thymic Organoid from Human Pluripotent Stem Cells
Abstract: The thymus is an integral part of the adaptive immune system as it generates T cells. Its function diminishes rapidly as the body ages, leading to a compromise of the immune system in the elderly. Reconstitution of adaptive immunity through mass production of different T cell types is therefore a therapeutic need in immunocompromised populations....
Published: 4/22/2025   |   Inventor(s): Raul Sakoda, Nicholas Restifo
Keywords(s): Aging, IMMUNOCOMPROMISED, Immunotherapy, Natural Killer T Cells, NKT, Organogenesis, Organoid, Pluripotent Stem Cells, T Cells, THYMUS, Vizcardo
Category(s): Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Immunology, Collaboration Sought > Licensing
3-o-sulfo-galactosylceramide Analogs for Targeting Lung Metastases
Summary: Lung metastases represent a major clinical challenge in advanced cancer, with poor survival rates and no effective therapies to prevent their development. Researchers at the National Cancer Institute (NCI) have developed C24:2, a first-in-class synthetic 3-O-sulfo-galactosylceramide analog. After lysosomal processing by dendritic cells, C24:2...
Published: 9/15/2025   |   Inventor(s): Lise Pasquet, Jay Berzofsky, Amy Howell, Masaki Terabe, Kaddy Camara
Keywords(s): 3-o-sulfo-galactosylceramide Analogs, Berzofsky, C24:2, Immunotherapy, lung cancer, Metastasis, Natural Killer cells, NKT cells, Sulfatide Analogs, T Cells
Category(s): TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Immunology
Improved Personalized Cancer Immunotherapy
Abstract: Scientists at NIH have identified a process to select highly tumor-reactive T cells from a patient tumor sample based on the expression of four specific T cell surface markers: programmed cell death protein 1 (PD-1; CD279), 4-1BB (CD137), T cell lg-and mucin-domain-containing molecule-3 (TIM-3), and/or lymphocyte activation gene 3 (LAG-3)....
Published: 4/22/2025   |   Inventor(s): Alena Gros, Steven Rosenberg
Keywords(s): adoptive cell transfer (ACT), T Cells, tumor infiltrating leukocytes (TIL)
Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology
Tethered Interleukin-15 (IL-15)/IL-21 to Enhance T Cells for Cellular Therapy
Abstract: Interleukin-15 (IL-15) and IL-21 have been reported to support the function of anti-tumor T cells.  However, their use in the clinic has been constrained, in part, by dose-limiting toxicity and the need for repeated administration.  To overcome these limitations, researchers in the National Cancer Institute (NCI) Experimental Transplantation...
Published: 4/22/2025   |   Inventor(s): Christian Hinrichs, Benjamin Jin
Keywords(s): act, adoptive cell therapy, CANCER, CAR, chimeric antigen receptor, Hinrichs, IL-15, IL-21, INTERLEUKIN-15, Interleukin-21, T Cells
Category(s): TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Licensing